Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

Adrian R. Levy; Peter Chen; Karissa Johnston; Yan Wang; Evan Popoff; Ioannis Tomazos

doi:10.1080/13696998.2022.2027706

Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

Adrian R. Levy, Peter Chen, Karissa Johnston, Yan Wang, Evan Popoff, Ioannis Tomazos

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	249-259
页数	11
期刊	Journal of Medical Economics
卷	25
期	1
DOI	https://doi.org/10.1080/13696998.2022.2027706
出版状态	已出版 - 2022
已对外发布	是

!!!ASJC Scopus Subject Areas

卫生政策

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1080/13696998.2022.2027706

其它文件与链接

引用此

@article{b8e22add92084aceb39a99ea2dfe38d1,

title = "Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome",

keywords = "aHUS treatment, caregiver productivity, cost minimization model, lost productivity, ravulizumab",

author = "Levy, {Adrian R.} and Peter Chen and Karissa Johnston and Yan Wang and Evan Popoff and Ioannis Tomazos",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

doi = "10.1080/13696998.2022.2027706",

language = "English",

volume = "25",

pages = "249--259",

journal = "Journal of Medical Economics",

issn = "1369-6998",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

AU - Levy, Adrian R.

AU - Chen, Peter

AU - Johnston, Karissa

AU - Wang, Yan

AU - Popoff, Evan

AU - Tomazos, Ioannis

PY - 2022

Y1 - 2022

KW - aHUS treatment

KW - caregiver productivity

KW - cost minimization model

KW - lost productivity

KW - ravulizumab

UR - http://www.scopus.com/inward/record.url?scp=85124850927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124850927&partnerID=8YFLogxK

U2 - 10.1080/13696998.2022.2027706

DO - 10.1080/13696998.2022.2027706

M3 - Article

C2 - 35020547

AN - SCOPUS:85124850927

SN - 1369-6998

VL - 25

SP - 249

EP - 259

JO - Journal of Medical Economics

JF - Journal of Medical Economics

IS - 1

ER -

Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此